{"id":245,"date":"2023-10-13T10:00:00","date_gmt":"2023-10-13T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=245"},"modified":"2025-09-10T09:41:43","modified_gmt":"2025-09-10T09:41:43","slug":"china-bd-2021-allist-pharma-and-arrivent-enters-a-150-million-usd-license-on-egfr-tki-furmonertinib","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/245.html","title":{"rendered":"[China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC\u00a0YL202 (BNT326)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2023-10-12 (October 12, 2023)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: YL202 (BNT326)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor (Seller):  MediLink Therapeutics (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): BioNTech<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: ADC (antibody drug conjugate)\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: Human Epidermal Growth Factor Receptor 3 (HER3)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication: Various cancer types, such as non-small cell lung cancer and breast cancer\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Stage until the Deal: \u00a0Phase 1<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink\u2019s ADC assets excluding Mainland China, Hong Kong and Macau. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment totaling of $70 million,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Development, regulatory and commercial milestone payments potentially totaling over $1 billion. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.medilinkthera.com\/news-details\/27\">Medilink Therapeutics<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of \u201cMediLink Therapeutics\u201c\uff0c\u5b9c\u8054\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-10-12 (October 12, 2023) Asset Name: YL202 (BNT326) Licensor (Seller): MediLink Therapeutics (China) Licensee &hellip; <a title=\"[China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC\u00a0YL202 (BNT326)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/245.html\"><span class=\"screen-reader-text\">[China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC\u00a0YL202 (BNT326)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-245","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=245"}],"version-history":[{"count":3,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/245\/revisions"}],"predecessor-version":[{"id":286,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/245\/revisions\/286"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}